VITRAFY LIFE SCIENCES PREP IPO BOOKBUILD FOR $117.5 MILLION FLOAT

Vitrafy Life Sciences, our local specialists in biomedical cryopreservation, are launching an IPO bookbuild. The early-stage company could be hitting the ASX boards with a $117.5 million market capitalisation, by November 27. Vitrafy wants to raise $25 million to $35 million at $1.84 a share, at an enterprise valuation of $79.1 million to $79.8 million.